Cigarette Smoke Exposure and the Acute Respiratory Distress Syndrome*
Year: 2015
Type: article
Study design: Observational Study
Abstract: OBJECTIVE: The association between cigarette smoke exposure and the acute respiratory distress syndrome in patients with the most common acute respiratory distress syndrome risk factors of sepsis, pneumonia, and aspiration has not been well studied. The goal of this study was to test the association between biomarker-confirmed cigarette smoking and acute respiratory distress syndrome in a diverse cohort. DESIGN: Prospective cohort. SETTING: Tertiary care center. PATIENTS: Four hundred twenty-six critically ill patients with acute respiratory distress syndrome risk factors (excluding trauma and transfusion) INTERVENTIONS: : None. MEASUREMENTS AND MAIN RESULTS: We obtained smoking histories and measured urine 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanol (a biomarker of cigarette smoke exposure) on urine samples obtained at the time of study enrollment. The association between cigarette smoke exposure and acute respiratory distress syndrome differed based on acute respiratory distress syndrome risk factor (p < 0.02 for interaction). In patients with nonpulmonary sepsis as the primary acute respiratory distress syndrome risk factor (n = 212), 39% of those with acute respiratory distress syndrome were current smokers by history compared with 22% of those without acute respiratory distress syndrome (odds ratio, 2.28; 95% CI, 1.24-4.19; p = 0.008). Likewise, cigarette smoke exposure as measured by urine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol was significantly associated with acute respiratory distress syndrome in this group. The increased risk of acute respiratory distress syndrome in nonpulmonary sepsis was restricted to patients with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol levels consistent with active smoking and was robust to adjustment for other acute respiratory distress syndrome predictors. Cigarette smoke exposure as measured by history or 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol was not associated with acute respiratory distress syndrome in patients with other risk factors (e.g., pneumonia and aspiration). CONCLUSIONS: Cigarette smoking measured both by history and biomarker is associated with an increased risk of acute respiratory distress syndrome in patients with nonpulmonary sepsis. This finding has important implications for tobacco product regulation and for understanding the pathogenesis of acute respiratory distress syndrome.
Source: Critical Care Medicine
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: American Heart Association, Pfizer, AstraZeneca, GlaxoSmithKline, Tobacco-Related Disease Research Program, Flight Attendant Medical Research Institute, Alere, Cumberland Pharmaceuticals, National Institutes of Health, National Heart, Lung, and Blood Institute, National Institute on Drug Abuse, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Research Resources, Center for Tobacco Products
Awards: G1112923544, G1894668648, G2017985641, G2571159024, Midcareer Investigator Award in Patient-Oriented Research in Acute Lung Injury, Clinical and Transtional Science Institute, G3422402278, G3429402575, G3437117843, Safety of Nicotine Reduction Strategy, G3723776939, G375803958, G3768891998, G3863507669, Impact of Cigarette Smoke Exposure on Acute Lung Injury, Drug Dependence Clinical Research Program, Improved Models to Inform Tobacco Product Regulation, G6244977906, G6507731378, G6679871049, G678201569, Chemokine-related acute lung injury pathogenesis in African-American patients, G8143143399, Biomarker Profiles in the Diagnosis/Prognosis of ARDS, G8715424652, Inflammatory and epithelial injury markers for ARDS prognosis:A validation study, G9000125503, G9000134530, G9000161121, G9000170049, G9000224224, Clinical and Translational Training Program in Pulmonary Medicine, Resolution of Clinical Lung Injury
OpenAlex ID: W1816622697
